Table 2.
Results for the primary and secondary outcomes.
| Liver function | Patients (n)/number of studies | WMD (95% CI) | I2 | P-value |
|---|---|---|---|---|
| Mild vs. Severe COVID-19 | ||||
| Aspartate aminotransferase, U/L | 2,215 (17) | 12.23 [8.07, 16.39] | 99% | <0.0001 |
| Alanine aminotransferase, U/L | 2,215 (17) | 8.08 [4.04, 12.11] | 98% | <0.0001 |
| Albumin, g/L | 1,408 (10) | −5.89 [−9.31, −2.46] | 100% | 0.0008 |
| Total Bilirubin g/L | 1,408 (9) | 2.32 [1.54, 3.10] | 94% | <0.00001 |
| Prothrombin time in seconds | 627 (5) | 0.66 [0.43, 0.89] | 89% | <0.00001 |
| Survivor vs. Non-survivors in COVID-19 | ||||
| Aspartate aminotransferase, U/L | 174 (4) | 8.82 [2.27, 15.37] | 98% | 0.008 |
| Alanine aminotransferase, U/L | 755 (5) | 4.70 [0.04, 9.35] | 97% | 0.05 |
| Albumin in g/L | 426 (5) | −3.69 [−4.43, −2.95] | 95% | <0.00001 |
| Total Bilirubin g/L | 4.04 [1.90, 6.18] | 4.04 [1.90, 6.18] | 52% | 0.0002 |
| Prothrombin time in seconds | 582 (4) | 0.71 [0.29, 1.13] | 96% | 0.001 |
WMD, Weighted mean difference; CI, Confidence interval; I2, inconsistency index; COVID-19, Coronavirus disease 2019.